Startups
Edit
Free PDF Hosting
http://freepdfhosting.com/0e3f19bd41.pdfLast activity: 27.07.2023
Probably Closed
Website visits
19.6K /mo.
Mentions
369
Overview
Location
United States, Michigan, Garden City
Employees
11-50
Mentions in press and media 369
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 26, 2023 | FDA inspection underscores problem at major U.S. compounder behind hospital drug recalls | One of the largest compound pharmacy operations in the U.S. recently recalled a slew of injectable medicines used by hospitals over concerns about possible side effects and a newly released regulatory report underscores the extent of the pr... |
| Jul 21, 2023 | Major pharma companies call on their suppliers to reduce carbon footprints | As anxiety mounts over climate change, seven of the world’s largest drugmakers urged dozens of their suppliers to outline targets they expect them to reach over the next few years in order to reduce carbon footprints. In explaining their ac... |
| Jul 20, 2023 | Damages from tornado at Pfizer plant could compound challenges of drug shortages | The tornado that struck parts of North Carolina on Wednesday not only damaged the immediate area, but could soon make it much harder for countless people across the U.S. and around the world to obtain needed medicines the next time they vis... |
| Jul 17, 2023 | Colombian government explores compulsory licensing for an HIV drug | The latest clash over the cost of a prescription medicine is playing out in Colombia, where the government is exploring the possibility of issuing a compulsory license for a needed HIV treatment — a move that would spark another battle with... |
| Jul 6, 2023 | Generic group sues Minnesota over a drug pricing transparency law it calls an ‘unconstitutional overreach’ | The trade group for generic drug companies has filed a lawsuit alleging a Minnesota law that is designed to provide transparency into prescription drug pricing is unconstitutional, the latest effort to push back against states attempting to... |
| Jun 29, 2023 | SEC charges former Pfizer statistician with insider trading over Paxlovid clinical trial results | A former Pfizer statistician on Thursday was charged by U.S. authorities with insider trading for acting on advance information about trial results for the Paxlovid Covid-19 treatment. The U.S. Securities and Exchange Commission alleged tha... |
| Jun 27, 2023 | Lilly reaches $2.4 million settlement with EEOC over age discrimination lawsuit | Eli Lilly agreed to pay $2.4 million as part of a settlement with the U.S. Equal Employment Opportunity Commission, which had filed a lawsuit accusing the company of age discrimination in hiring sales representatives around the country over... |
| Jun 21, 2023 | PhRMA sues Biden administration over Medicare drug price negotiation program | WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts. The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing ... |
| Jun 6, 2023 | ‘Tantamount to extortion’: Merck sues U.S. government over Medicare negotiation program | WASHINGTON — Merck on Tuesday sued to stop the federal government from implementing a new Medicare drug price negotiation program. Merck called the negotiation process that Democrats designed in a law last August “a sham,” arguing that the ... |
| May 30, 2023 | Sacklers win appeal that shields them from opioid lawsuits, clearing way for bankruptcy settlement | A federal appeals court ruled Tuesday Purdue Pharma can shield its owners — members of the wealthy Sackler family — from thousands of lawsuits over the role the company played in the opioid crisis in exchange for a contribution of up to $6 ... |
| Mar 29, 2023 | Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs | A growing shortage of monkeys used for early-stage pharmaceutical research is causing concern that many companies will soon face costly delays starting clinical trials — leading to a slowdown in drug development. In recent weeks, the U.S Fi... |
| Mar 27, 2023 | Ohio attorney general accuses pharmacy benefit managers of drug price fixing | The Ohio attorney general filed a lawsuit on Monday accusing three large pharmacy benefit managers of fixing prices for various medicines, the latest effort to scrutinize the controversial companies that occupy a crucial role in pharmaceuti... |
| Feb 24, 2023 | A dozen states sue the FDA in hopes of easing abortion pill restrictions | In the latest flare up over access to the abortion pill, a dozen states filed a lawsuit to force the U.S. Food and Drug Administration to ease restrictions on how mifepristone is prescribed and made available to patients. At issue is a risk... |
| Jan 20, 2023 | FTC wants ‘pharma bro’ Martin Shkreli held in contempt for violating lifelong ban on working in pharma | The Federal Trade Commission asked a federal judge to hold “pharma bro” Martin Shkreli in contempt for failing to provide the agency with information needed to determine whether he is violating an order that permanently banned him from work... |
| Dec 12, 2022 | Cambodia halts exports of non-human primates, threatening drug discovery efforts | Following the recent indictments of several people allegedly involved in a monkey-smuggling operation, Cambodia has halted exports of non-human primates that are widely used in pharmaceutical research, a move that may crimp drug discovery e... |
| Dec 7, 2022 | FDA scolds company that raised red flags over impurities in many widely used medicines | Two years after an independent laboratory began pushing the Food and Drug Administration to analyze various medicines for traces of carcinogens, the agency sent inspectors to the company and cited it for failing to comply with federal law. ... |
| Dec 7, 2022 | Pharmalittle: Zantac lawsuits tossed over inadequate scientific evidence; Lilly tightens access to diabetes drug used for weight loss | Good morning, everyone, and how are you today? We are doing just fine, thank you. Given that this is already the middle of the week and we have survived this far, no reason not to continue, yes? Just consider the alternatives. In fact, this... |
| Dec 6, 2022 | Zantac lawsuits are tossed out as judge lambasts lack of evidence showing links to cancer | Several big drugmakers — Sanofi, GSK, Pfizer and Boehringer Ingelheim — will not have to face thousands of lawsuits claiming the Zantac heartburn drug can cause cancer after a federal judge decided consumers’ claims were not backed by sound... |
| Nov 15, 2022 | ‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process | As the Covid-19 pandemic spread across the world two years ago, one of India’s leading biotech companies was racing to develop a vaccine with crucial backing from the Indian government. The shot engineered by Bharat Biotech was, in part, an... |
| Jun 21, 2022 | Senate lawmakers introduce a bill to help the FDA and the U.S. Patent Office coordinate | Amid concerns that patent reviewers disregard competitive effects on prescription drugs, a bipartisan group of senators introduced a bill to require the Food and Drug Administration and the Patent & Trademark Office to create a task for... |
| Apr 14, 2022 | Bristol Myers agrees to settle lawsuit alleging anti-competitive deals involving HIV drugs | After three years of squabbling, Bristol Myers Squibb has agreed to pay up to $11 million to settle a lawsuit that accused several drugmakers of conspiring to block generic competition to HIV medicines. The lawsuit described an unusual sche... |
| Apr 6, 2022 | STAT-Harris Poll: Most Americans would get a Covid-19 booster shot if recommended | As a Food and Drug Administration panel meets Wednesday to sort out the ongoing use of booster shots for Covid-19, a new survey by STAT and The Harris Poll finds six in 10 Americans have already decided they will get another booster if it’s... |
| Apr 6, 2022 | Pharmalittle: Most Americans would get a second booster shot; FDA pulls Glaxo Covid treatment | Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While... |
| Mar 28, 2022 | Vertex strikes agreement with Australia for cystic fibrosis pill, ending high-profile standoff | Vertex reached an agreement on Sunday to sell its newest cystic fibrosis drug in Australia, ending a high-profile standoff over access to a life-altering but expensive rare disease drug. As with most agreements between dru... |
| Mar 22, 2022 | Aurobindo, major generic drug maker, will close a key U.S. production plant | Aurobindo Pharma, which is based in India and is one of the largest global producers of generic medicines, is closing its U.S. manufacturing facility in New Jersey next month, according to a notice filed with the state Department of Labor. ... |
| Mar 3, 2022 | Sacklers agree to $6 billion Purdue bankruptcy settlement over opioid crisis | The Sackler family members who own Purdue Pharma have agreed to pay up to $6 billion to settle a hotly contested bankruptcy plan, which will allow state governments and tens of thousands of people to be compensated for the company’s role in... |
| Mar 1, 2022 | Tennessee judge sanctions Endo for withholding opioid documents, refuses to recuse himself from case | Endo International (ENDP) was sanctioned by a Tennessee state court judge for using a “coordinated strategy” to withhold millions of documents in a lawsuit contending the company contributed to the opioid crisis, the second time in less tha... |
| Feb 16, 2022 | BioNTech details new plans for Covid-19 vaccine production in Africa, but meets with skepticism | Amid escalating concern over global access to Covid-19 vaccines, BioNTech (BNTX) disclosed details about its plans to boost production in Africa. But the effort was met with a mixed reaction because the approach snubs a parallel effort by t... |
| Feb 7, 2022 | ‘Caught in the middle’: Some patients say they’ve lost out in unusual battle over a rare disease drug | An unusual, decade-long fight over an orphan drug market appears to be at an end after a small, family-run company was defeated in a bruising battle with a rival and has now lost regulatory approval of its medicine. Late last month, a feder... |
| Feb 7, 2022 | In a victory for medical journals, Pacira loses a libel lawsuit over ‘faulty scientific research’ allegations | A federal judge has dismissed an unusual libel lawsuit brought by Pacira BioSciences (PCRX) that claimed a medical journal, its editor, and the authors of several papers published articles that were based on “faulty scientific research” tha... |
| Feb 3, 2022 | Pfizer sues two former employees for stealing trade secrets and creating a rival for diabetes and obesity drugs | Pfizer (PFE) has accused two former employees of clandestinely creating a pair of companies that are now using stolen trade secrets to develop obesity and diabetes medicines, which recently prompted Eli Lilly (LLY) to strike a collaboration... |
| Feb 3, 2022 | PhRMA takes aim at WHO and European Union over support of weakening patent protections | Amid growing concern over access to Covid-19 vaccines and treatments, the U.S. pharmaceutical industry trade group has lashed out at the World Health Organization and other global agencies for supporting efforts to pause patent rights in ho... |
| Jan 26, 2022 | Pharmalittle: Gilead faces partial clinical hold on blood cancer drug; Rhode Island agrees to opioid deal with wholesalers | Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made it this far, which is a likely sign of surviving a... |
| Jan 25, 2022 | Insufficient progress is being made in reporting clinical trial results in the U.S. | As scrutiny into clinical trial disclosure intensifies, a new analysis finds that a number of leading U.S. universities and hospitals are still failing to report clinical trial results to a federal database. The findings reflect little chan... |
| Jan 6, 2022 | Chilean health ministry is urged to issue a compulsory license for the Pfizer Covid pill | In the latest bid to expand access to the Pfizer (PFE) Covid-19 pill, a nonprofit group and an association of pharmacists are seeking to make it possible for generic manufacturers to sell the medicine in Chile, which was excluded from a rec... |
| Jan 6, 2022 | Institutional investors urge pharma boards to tie executive compensation to global Covid vaccine equity | More than 65 institutional investors are urging the directors of companies making Covid-19 vaccines to tie executive compensation to vaccine equity in hopes of holding management “accountable” for contributing to a global health problem. In... |
| Jan 3, 2022 | HHS appeals rulings over drug discount program just as AbbVie is latest to cut discounts | A heated clash over a U.S. government drug discount program has intensified after a federal agency appealed several recent court rulings that questioned its approach to enforcing a decades-old initiative. At the same time, AbbVie became the... |
| Dec 20, 2021 | AbbVie petitions trade commission to ban Alvotech's Humira biosimilar; Cytokinetics licenses heart drug to Chinese partner | The AbbVie/Alvotech debacle on a Humira biosimilar has taken yet another turn — escalating tensions between the two biotechs. As first reported by STAT News, the pharma giant filed a complaint with the US Internation... |
| Dec 16, 2021 | FDA rebukes Endo for ‘anticompetitive practices’ and asks FTC to investigate | In an unusual move, the U.S. Food and Drug Administration has openly suggested that a brand-name drug maker attempted to delay competition after it petitioned the agency to reject generic versions of its biggest-selling medicine. As a resul... |
| Dec 10, 2021 | Generic drug makers win a court round as judge temporarily blocks California pay-to-delay law | In a victory for generic drug makers, a federal court judge temporarily blocked a controversial California law that bans so-called pay-to-delay deals between pharmaceutical companies, a contentious issue that has factored into the larger de... |
| Dec 9, 2021 | Viatris and Biocon mull pooling their biosimilars into a $10B standalone company — report | A class action lawsuit from two former sales representatives has been filed in US District Court, accusing Eli Lilly of age discrimination throughout its hiring process and going as far as to allege that the Big Pharma hired younger workers... |
| Nov 28, 2021 | Pfizer sues former employee for allegedly stealing Covid-19 vaccine documents | Amid the intense race to develop Covid-19 products, Pfizer (PFE) accused a former employee of stealing more than 12,000 files — including scores of confidential documents — that contained information about its coronavirus vaccine as well as... |
| Nov 6, 2021 | New court rulings add to the confusing and controversial dispute over a U.S. drug discount program | In the latest twist in a closely watched legal battle, two different federal court judges late last week reached largely conflicting views about the approach taken by the U.S. government to enforce a controversial prescription drug discount... |
| Nov 2, 2021 | California judge sides with drugmakers in $50B opioid lawsuit | A Superior Court judge in California ruled Monday that opioid manufacturers were not responsible for the crisis because of their misleading marketing, Stat News reports. Three California counties, as well as the ci... |
| Oct 20, 2021 | Gates Foundation will provide $120 million to ensure generic production of Merck’s Covid-19 pill | As concern mounts over access to Covid-19 remedies, the Bill & Melinda Gates Foundation is committing up to $120 million to accelerate production of generic versions of an experimental Merck (MRK) pill to treat Covid-19 that would be av... |
| Oct 3, 2021 | Pfizer loses a lawsuit alleging the U.S. illegally limits use of patient copay assistance programs | In a setback to the pharmaceutical industry, a federal judge ruled that programs Pfizer (PFE) wanted to launch to provide copay assistance to Medicare patients would likely violate kickback laws, a controversial notion that has caused numer... |
| Sep 4, 2021 | Abrupt FDA exits spark concern; Unpacking key concepts at gene therapy summit; 20 luminaries who reshaped R&D; and more | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to... |
| Sep 3, 2021 | Ziopharm finds new CEO after six-month search; CFO transition at Lonza to take place in December | Kevin Boyle Less than a year removed from a successful activist attack, Ziopharm Oncology appointed a new CEO this week. Taking the reins will be Kevin Boyle, who comes over after leading Kuur Therapeutics to a $185 milli... |
| Sep 3, 2021 | Bristol Myers licenses for Evotec molecule for $20M; FDA approves Impel's migraine nasal spray Trudhesa | Bristol Myers Squibb has exercised its option with Evotec for EVT8683, a small molecule created by the German biotech to target a specific “cellular stress response.” The companies have obtained clearance to start human... |
| Sep 3, 2021 | Sister to Juno's liso-cel, JW's relma-cel lands second-ever CAR-T approval in China | Juno may have stumbled its way to a distant third finish in the CD19 CAR-T race, but its joint venture in China is heading off to a thriving start. JW Therapeutics, which took its name from co-founders Juno and WuXi AppTec, has sc... |
| Sep 2, 2021 | Hot off of a $210M Series B, Umoja breaks ground in Colorado on CAR-T site | Boulder County, CO, is getting a new manufacturing facility, and it will come from a Seattle oncology company focused on CAR T-cell immunotherapies. Umoja Biopharma broke ground on a new facility for in vivo immu... |
| Aug 31, 2021 | In a major blow to vaccine efforts, senior FDA leaders stepping down | A private equity group has joined hands with a sovereign wealth fund out of Singapore to strike a deal to buy Swedish Orphan Biovitrum — a high-profile rare disease player better known as Sobi — for $8 billion and take the company private. ... |
| Aug 31, 2021 | In a major blow to vaccine efforts, senior FDA leaders stepping down | A program touted by Novartis CEO Vas Narasimhan as a near-slam dunk has flopped a Phase IIb study, leading the Swiss biopharma to discontinue the trial altogether. The candidate in question, iscalimab or CFZ533, proved less effective than s... |
| Aug 31, 2021 | In a major blow to vaccine efforts, senior FDA leaders stepping down | Two prominent House committees are digging deeper into the FDA’s cozy relationship with Biogen as it reviewed and approved its new Alzheimer’s drug Aduhelm. While the committees were briefed by FDA on the situation in mid-July, the chairs a... |
| Aug 17, 2021 | Former Medivation exec charged with insider trading after buying stock ‘within minutes’ of learning of a deal | Just days before Pfizer (PFE) announced plans to acquire Medivation six years ago, the former head of business development at Medivation bought stock in yet another company that Wall Street bankers deemed equally desirable. Now, he has been... |
| Aug 16, 2021 | Pharmalittle: Merck is latest drug maker to end 340B discounts; ‘fractionation’ is promoted to stretch Covid-19 vaccines | Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because … well, you know … the predictable routine of online meetings and deadlines has resumed. Despite the tumult, the ... |
| Jul 27, 2021 | Purdue says most creditors voted in favor of contentious bankruptcy plan | In an apparent victory for Purdue Pharma, preliminary voting shows most creditors are in favor of its controversial bankruptcy plan, an outcome that, if confirmed, suggests the company and its infamous owners are closer to resolving sweepin... |
| Jul 19, 2021 | Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels | Never mind the conflicts, there are drugs to approve. In a sorry turn of events, the Food and Drug Administration is facing a confidence-draining debacle thanks to its controversial approval of a pricey Alzheimer’s drug for which evidence a... |
| Jul 9, 2021 | FDA extends shelf life for glaucoma drug discontinued by Pfizer, but patients remain concerned | In a bid to calm anxious patients, the Food and Drug Administration has extended the shelf life of a drug used to treat a rare form of glaucoma, which Pfizer (PFE) recently discontinued and which may disappear altogether unless the company ... |
| Jul 8, 2021 | Purdue reaches deal with 15 states in a significant step toward bankruptcy plan approval | Fifteen states have agreed to drop their long-standing objections to a contentious bankruptcy plan to reorganize Purdue Pharma, a significant step that will likely ensure the proposal will be approved in court next month. As part of the dea... |
| Jul 2, 2021 | Purdue wants to shower employees with nearly $35 million in different kinds of bonuses | As Purdue Pharma attempts to win a controversial reorganization plan in bankruptcy court, the drug maker is also seeking approval for $34.7 million in employee bonuses, including $2.1 million for the chief executive officer. The request, wh... |
| Jun 22, 2021 | Teva agrees to pay $925,000 to Mississippi to settle generic price-fixing charges | After years of controversy, Teva Pharmaceuticals (TEVA) agreed to pay $925,000 to the state of Mississippi to settle allegations of conspiring to set prices of generic medicines, the first instance in which a state and drug maker have reach... |
| Jun 16, 2021 | Lawmakers revive legislation to accelerate the development of new antibiotics | After months of anticipation, a bipartisan group of U.S. lawmakers is reintroducing bills in the Senate and the House that supporters hope will jump-start the development of novel antibiotics to combat drug-resistant bacteria. The legislati... |
| Jun 16, 2021 | ‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval | Reacting to the controversial approval of the Biogen (BIIB) Alzheimer’s drug, a leading advocacy group is urging the Biden administration to request resignations from or remove three top Food and Drug Administration officials, including act... |
| May 20, 2021 | ‘There’s so much uncertainty’: As Mallinckrodt sells rare disease drug, parents worry about access | As it looks to emerge from bankruptcy, Mallinckrodt (MNK) has sold an experimental medicine that until recently was being tested to treat a fatal genetic disorder. But the company has said it will work with the buyer to ensure it remains av... |
| Apr 21, 2021 | Most Americans say they should be vaccinated before the U.S. donates Covid-19 shots elsewhere | Three-quarters of Americans believe the U.S. government should start donating Covid-19 vaccines to other countries, but only after every person in the U.S. who wants a vaccine has received one, according to a new survey from STAT and The Ha... |
| Apr 16, 2021 | In highly unusual move, Pacira sues medical journal for libel over its non-opioid painkiller | A New Jersey biotech whose only approved drug is used as a painkiller after surgeries is suing a scientific journal, its editors and a handful of authors for libel after the publication printed numerous papers and ed... |
| Apr 15, 2021 | A drug maker sues a medical journal, its editor, and several authors for libel | In an unusual move, Pacira Biosciences (PCRX) has filed a libel lawsuit against a medical journal, its editors, and the authors of several recently published papers, arguing the articles were based on “faulty scientific research” and as a r... |
| Apr 7, 2021 | Judge rules Purdue must answer questions about documents showing any link between OxyContin, birth defects | A federal judge has given a green light to lawyers representing children with birth defects — allegedly due to exposure to opioids in utero — to question Purdue Pharma over efforts to provide documents concerning any links to its addictive ... |
| Apr 2, 2021 | Bristol Myers Squibb agrees to pay $75 million to settle allegations of underpaying Medicaid rebates | After years of litigation, Bristol Myers Squibb (BMY) agreed to pay $75 million, plus interest, to resolve allegations of knowingly underpaying rebates that were owed to state Medicaid programs. The settlement, which the company had signale... |
| Mar 30, 2021 | After dismissing CFO over 'inappropriate messages,' Eli Lilly faces new accusations of sexual discrimination and harassment | A month after ousting CFO Josh Smiley for sending “inappropriate messages” to employees, Eli Lilly is facing new allegations that an executive and a senior manager at its Washington, DC office sexually discrimi... |
| Mar 24, 2021 | UPDATED: AbbVie accuses rival of stealing blockbuster ‘trade secrets’ as clock ticks down on biosimilar assault | Two years before the first biosimilars to megablockbuster Humira are expected to hit the US market, AbbVie is taking one developer to court over allegations it stole trade secrets to create its copycat version. AbbVi... |
| Mar 23, 2021 | AbbVie accuses a company of recruiting an employee in order to steal Humira secrets | Two years ago, a manufacturing team leader at AbbVie (ABBV) took a similar job at an erstwhile rival that planned to make a biosimilar version of Humira, its best-selling product. But before leaving, the employee allegedly transferred a raf... |
| Mar 19, 2021 | ‘The public is being denied the truth’: A legal expert blasts Purdue’s bankruptcy plan to end opioid lawsuits | Earlier this week, Purdue Pharma filed a bankruptcy plan that would have some members of the Sackler family, which owns the drug company, relinquish control and pay nearly $4.3 billion to reimburse states, cities, and tribes for the costs a... |
| Feb 17, 2021 | Janet Woodcock slams calls for FDA 'firewall' amid aducanumab debacle, citing need for collaborative drug development | The FDA has long taken a collaborative approach to working with drugmakers on approval applications, all in the interest, it says, of bringing the best molecules to market. But when the drug is a lemon, the cozy relatio... |
| Feb 16, 2021 | Once again, senators want GAO to probe the role of PBMs in prescription drug pricing | In a bid to contain prescription drug prices, a pair of U.S. senators is re-introducing a bill to have the Government Accountability Office probe the role of pharmacy benefit managers in the opaque pharmaceutical supply chain. The legislati... |
| Feb 15, 2021 | STAT-Harris Poll: 1 in 4 Americans were unable to get a Covid-19 test when they wanted one | As the U.S. struggles to contain the Covid-19 pandemic, nearly a quarter of Americans say they wanted to get tested for the coronavirus but were unable to do so, according to the latest survey from STAT and The Harris Poll. Specifically, 24... |
| Feb 4, 2021 | Ramona Sequeira to become PhRMA's first female chair; McKinsey reaches nearly $574 million settlement over involvement in opioid crisis | PhRMA is getting its first female board chair. On Thursday, the trade association celebrated news that Ramona Sequeira, president of Takeda’s US business, has been named chair-elect. The former board treasurer is set to s... |
| Jan 21, 2021 | Canada’s drug makers rattle their sabers over a government plan to control medicine spending | A majority of pharmaceutical executives in Canada say new regulations designed to cut prescription drug spending by the Canadian government are delaying product launches and R&D investment and will subsequently hurt employment, accordin... |
| Jan 7, 2021 | Generic drug makers fear a ‘skinny labeling’ court ruling will pose a huge threat | An arcane regulatory term known as skinny labeling may have a funny ring to it, but to generic drug makers, it is no laughing matter. What has the generic industry upset is a recent court ruling that, legal experts say, could effectively ne... |
| Dec 21, 2020 | STAT-Harris Poll: Most Americans would support Biden issuing a mask mandate | Most Americans believe the Biden administration should mandate several steps — such as requiring people to wear masks in public and banning gatherings of 10 or more people — to thwart the Covid-19 pandemic, according to the latest survey fr... |
| Dec 20, 2020 | Sacklers withdrew cash from Purdue after opioid lawsuit fears were raised, documents show | In recent weeks, different members of the Sackler family that controls Purdue Pharma maintained they did not foresee the massive amount of lawsuits that would blame their company for its role in the opioid crisis. And for this reason, they ... |
| Dec 18, 2020 | Former J&J VP sues pharma giant for discimination and harassment, accuses top execs — including Alex Gorsky — of retaliating against her | A former J&J exec has filed a lawsuit against the pharma giant for gender discrimination, unequal pay and retaliation leading to what she alleges is an abrupt and wrongful termination to her 25-year career at the c... |
| Nov 16, 2020 | Federal authorities issue strong warning to pharma over speaker programs and kickbacks | A federal watchdog agency has issued an unusual warning to the pharmaceutical industry to avoid using kickbacks — specifically, under the guise of so-called speaker programs — to entice doctors to write more prescriptions. In a special frau... |
| Oct 30, 2020 | Purdue law firm hires Justice Department lawyer who investigated the opioid maker | A prominent law firm that represents Purdue Pharma has hired a former Department of Justice lawyer who, as recently as seven months ago, was investigating the drug maker for its opioid marketing. In a court filing, King & Spalding discl... |
| Oct 16, 2020 | Pharmalittle: Study finds remdesivir fails to prevent Covid-19 deaths; Trump’s $200 discount drug cards hit snags | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, once again, is rather modest. We plan to catch up on some reading... |
| Oct 15, 2020 | Covid-19 roundup: Russia approves second vaccine, Putin says; Advocacy groups ask WTO to waive patent rights | Russia has approved a second Covid-19 vaccine, president Vladimir Putin announced Wednesday. Like its first, the country’s new vaccine did not undergo large-scale trials before approval. Putin said that the vaccine comes fro... |
| Oct 14, 2020 | Hundreds of advocacy groups urge WTO to waive IP rights to Covid-19 drugs and vaccines | Amid growing concern over access to Covid-19 medical products, hundreds of advocacy groups are urging the World Trade Organization to waive some provisions in a trade deal governing intellectual property rights so drugs and vaccines can be ... |
| Oct 13, 2020 | Ezekiel Emanuel on vaccines, Trump’s Covid-19 treatment, and what went wrong on the U.S. response | The controversy surrounding the Trump administration response to the Covid-19 pandemic grew still thornier after President Trump contracted the virus himself 11 days ago. The development quickly raised questions about the extent to which ac... |
| Oct 6, 2020 | Insulin in the U.S. cost up to 10 times more than in nearly three dozen other OECD countries | Amid raging debate over the cost of insulin, a new report finds prices in the U.S. were often five to 10 times higher two years ago than in all the other countries in the Organization for Economic Cooperation and Development, an intergovern... |
| Oct 6, 2020 | Medical experts urge FDA to adopt stricter safety standards for Covid-19 vaccines | As the race for a Covid-19 vaccine accelerates, dozens of leading medical experts are urging the Food and Drug Administration to adopt a stricter standard for tracking the safety of clinical trial participants. In a letter to the agency, th... |
| Oct 1, 2020 | Appeals court hands FTC a setback that invalidates its ability to claw back millions from AbbVie | A U.S. appeals court reversed a lower court ruling that required AbbVie (ABBV) and another company to disgorge $448 million in profits for filing “sham” patent litigation to keep generic versions of its blockbuster AndroGel treatment off of... |
| Sep 30, 2020 | For the first time, drug makers and PBMs must jointly face an insulin price fixing lawsuit | A federal judge ruled that a Texas county can proceed with a lawsuit accusing several drug makers and pharmacy benefit managers of conspiring to fix prices for insulin, the first time these companies will have to collectively defend their r... |
| Sep 29, 2020 | Catalyst loses lawsuit accusing the FDA of unfairly approving a rival rare disease drug | In a blow to Catalyst Pharmaceuticals (CPRX), a federal judge dismissed its lawsuit accusing the Food and Drug Administration of violating the law when it approved a similar medicine by a small, family-run rival company. The lawsuit has bee... |
| Aug 26, 2020 | Catalyst takes its fight over a rare disease drug to Canada, suing the country’s regulator | An unusual battle between two small companies over the market for a rare disease drug has now spread to Canada, where Catalyst Pharmaceuticals (CPRX) has gone to court in hopes of blocking a rival medicine sold by Jacobus Pharmaceuticals, a... |
| Jul 31, 2020 | In a blow to Catalyst, judge recommends tossing its lawsuit against FDA | A federal court judge recommended tossing a lawsuit filed by Catalyst Pharmaceuticals (CPRX) that accused the Food and Drug Administration of violating the law when it approved a similar medicine by a small, family-run rival company. The mo... |
| Jun 30, 2020 | Canadian court upholds most of a controversial new rule for controlling excessive drug prices | In a setback to the pharmaceutical industry, a Federal Court judge in Canada has dismissed a challenge by drug makers that contended controversial new government rules designed to regulate excessive pricing would inhibit innovation and hurt... |
| Jun 26, 2020 | Pfizer sues Trump administration over anti-kickback rules, saying they prevent it from helping lower seniors’ drug costs | WASHINGTON — Pharmaceutical giant Pfizer is suing the Trump administration over two long-standing Medicare rules that Pfizer says are blocking it from helping seniors pay for an expensive heart condition drug. The lawsuit, which was filed i... |
| Jun 18, 2020 | AbbVie-Allergan complete, but critics continue to raise anti-competitive concerns | The Abbvie-Allergan mega-merger may now be complete, but its critics haven’t had their last say. In a 7-page letter to the Federal Trade Commission, California Attorney General Xavier Becerra called into question the ... |
Show more
Reviews 0
FAQ about Free PDF Hosting
What has the press written about Free PDF Hosting?
Parsers VC has collected 369 articles mentioning Free PDF Hosting, among them “FDA inspection underscores problem at major U.S. compounder behind hospital drug recalls” (Jul 26, 2023) and “Major pharma companies call on their suppliers to reduce carbon footprints” (Jul 21, 2023).
Is Free PDF Hosting still active?
Free PDF Hosting is probably closed: its latest activity on Parsers VC dates from Jul 27, 2023.